EpimAb is a China-based clinical stage biotech company specializing in bispecific antibody development.
Employees: 11-50
Total raised: $219M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.06.2019 | Series B | $74M | - |
| 25.04.2017 | Series A | $25M | - |
| - | Series C | $120M | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.07.2025 | TCG Labs Soleil raises $400M for single-asset biotechs, expands R&D footprint to China | TCG Labs Soleil has secured $400 million to boost the firm’s ability to advance its biotech portfolio companies while also expanding its R&D capabilities globally. The San Francisco-based company’s fundraise is the exact same size as it... |
| 06.06.2019 | Fitness Startup Peloton Officially Begins Its Path to IPO: Term Sheet | THE CLIMB TO IPO Peloton, the home exercise equipment maker, has filed confidential IPO paperwork with the Securities and Exchange Commission. As my coworker recently characterized the company: “It’s the biggest thing in home exercise since... |
| 05.06.2019 | EpimAb Biotherapeutics Raises $74M in Series B Financing | EpimAb Biotherapeutics, a Shanghai, China-based biopharmaceutical company specializing in bispecific antibodies, closed a $74m USD Series B financing round. The round, which brings total funding so far to over $100M USD, was co-led by SDIC ... |
| 25.04.2017 | EpimAb Biotherapeutics Raises $25M in Series A Funding | EpimAb Biotherapeutics, a Shanghai, China-based biopharmaceutical company specializing in bispecific antibodies, closed a $25m Series A funding. The round was led by Oriza Seed Capital with participation from Decheng Capital, 3E Bioventures... |
| 25.04.2017 | Term Sheet — Tuesday, April 25 | MONEY-LOSING HOUSE OF HORRORS Contrarian: The message around Cloudera’s IPO, which is expected to price on Thursday after the market closes, has been yikes. The company was last valued at $4.1 billion; its share pricing values the company a... |
| 11.10.2016 | Kymab signs bispecific antibody agreement with EpimAb | Kymab signs bispecific antibody agreement with EpimAb 11-10-2016 Kymab Limited, a leading human monoclonal antibody biopharmaceutical company based at the Babraham Research Campus, and EpimAb Biotherapeutics, Inc., an emerging Chinese bioph... |
| - | EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline | SHANGHAI--(BUSINESS WIRE)--Mar 22, 2021-- EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120 million Series C financing round. The round was co-led... |